Analyse Kymera Therapeutics, Inc. (KYMR) — Kairos Score 68/100

À propos de Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

10 transactions — 0 achats et 9 ventes déclarés par les dirigeants de Kymera Therapeutics, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur KYMR dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur KYMR.

• Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
• Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.